UAB Alzheimer's Disease Center Core Cohort - Tau Imaging Substudy
Status:
Recruiting
Trial end date:
2024-07-08
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to measure the concentration and the regional brain
distribution of pathologic tau deposition using the PET tracer AV-1451 in participants in the
UAB-ADC cohort. The amount and distribution of AV-1451 in the brain will be correlated to
demographic, clinical, genetic, and biospecimen data acquired through the separate ongoing
UAB-ADC study. Assessment of interactions between race and vascular risk factors, brain tau
levels measured with AV-1451-PET, and cognitive status will be the primary outcome of this
imaging study. Individuals participating in this AV-1451-PET/MRI study will also be enrolled
in an ongoing [C-11]PiB-PET/MRI study (IRB-300001005, IND-138128), and their amyloid, tau and
cognitive statuses will be compared in terms of race and vascular risk factors.